Study guide
11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
Key Takeaways Explain This Topic AI
Ascending cholangitis is Charcot's triad of fever, jaundice and right upper quadrant pain, and requires urgent biliary decompression by ERCP.
The modified Glasgow criteria for severe acute pancreatitis are remembered as PANCREAS, and a score of 3 or more within 48 hours predicts severe disease.
Gallstones and alcohol account for most acute pancreatitis in the UK; hypertriglyceridaemia, hypercalcaemia, ERCP and drugs such as azathioprine are important secondary causes.
Last updated: September 2026
- 2. Gallstone Disease & Biliary Tract Infections
- Spectrum of Gallstone Pathology
Gallstones (cholelithiasis) affect 10–15% of the UK adult population (80% cholesterol stones, 15% black pigment stones [haemolysis, cirrhosis], 5% brown pigment stones [biliary stasis/infection]):
Biliary Colic: Transient impaction of a gallstone in the cystic duct during postprandial gallbladder contraction. Episodic, severe, constant epigastric or right upper quadrant pain radiating to the interscapular region or right shoulder, lasting 1–6 hours, resolving completely. Normal inflammatory markers (WBC, CRP) and normal liver biochemistry.
Acute Cholecystitis: Persistent cystic duct obstruction resulting in gallbladder distension, inflammation, and secondary bacterial infection ( E. coli , Klebsiella , Enterococcus ). Constant RUQ pain lasting >6 hours, accompanied by fever, leukocytosis, and elevated CRP.
Murphy's Sign: Inspiratory arrest elicited when the examiner's fingers palpate deeply under the right costal margin while the patient takes a deep breath.
Ultrasound Findings: Gallbladder wall thickening (>3–4 mm), pericholecystic fluid, gallstones, and sonographic Murphy's sign.
Treatment: IV fluids, IV antibiotics (co-amoxiclav), and early laparoscopic cholecystectomy (within 72 hours of admission).
Choledocholithiasis: Gallstone migration into the common bile duct (CBD). Causes colicky RUQ pain, obstructive jaundice (dark urine, pale stools), pruritus, elevated conjugated bilirubin, ALP, and GGT. Dilated CBD on ultrasound (>6 mm). Diagnosed via MRCP/EUS; managed via therapeutic ERCP sphincterotomy and stone extraction.
Acute Ascending Cholangitis: Life-threatening bacterial infection of an obstructed biliary tree. Elevated intrabiliary pressure facilitates bacterial translocation into the hepatic circulation, provoking rapid sepsis.
Charcot's Triad: (1) Right upper quadrant pain, (2) Jaundice, (3) Spiking fever with rigors. (Present in 50–70% of patients).
Reynolds' Pentad: Charcot's triad plus (4) Hypotension (septic shock) and (5) Altered mental status / confusion. Indicates toxic suppurative cholangitis with high mortality.
Emergency Management Protocol: Immediate fluid resuscitation, blood cultures, intravenous broad-spectrum antibiotics (piperacillin-tazobactam or meropenem), and urgent emergency biliary decompression via ERCP (sphincterotomy, stone extraction, or biliary stenting) within 24 hours (or within 12 hours if Reynolds' pentad or refractory septic shock).
- 3. Pancreatitis
- Acute Pancreatitis
Pathophysiology: Premature intracellular activation of pancreatic zymogens (conversion of trypsinogen to trypsin by lysosomal cathepsin B within acinar cells) leads to autodigestion of pancreatic parenchyma, microvascular thrombosis, acinar necrosis, and massive release of pro-inflammatory cytokines (TNF-alpha, IL-1, IL-6), provoking a Systemic Inflammatory Response Syndrome (SIRS).
Aetiology (Mnemonic GET SMASHED):
- G allstones (~45–50% of UK cases; transient impaction at ampulla of Vater)
- E thanol (~30–35% of UK cases; toxic alcohol metabolites e.g., fatty acid ethyl esters)
- T rauma (blunt abdominal trauma transecting pancreas across lumbar spine)
- S teroids (systemic glucocorticoid therapy)
- M umps (and other viruses: Coxsackie B, CMV, EBV, HIV)
- A utoimmune (Type 1 IgG4-related systemic pancreatitis vs Type 2 idiopathic duct-centric)
- S corpion sting (venom of Trinidadian scorpion Tityus trinitatis )
H yperlipidaemia (marked hypertriglyceridaemia: fasting serum triglycerides >11.3 mmol/L or >1000 mg/dL) / H ypercalcaemia (primary hyperparathyroidism; calcium activates intra-acinar trypsinogen)
E RCP (post-procedural pancreatitis in 3–5%; mitigated by prophylactic rectal diclofenac/indometacin)
D rugs: Azathioprine, 6-mercaptopurine, sodium valproate, thiazide diuretics, didanosine, mesalazine, ACE inhibitors
Diagnostic Criteria (Revised Atlanta Classification): Requires at least 2 of the following 3 features :
Acute onset of severe, persistent epigastric pain radiating to the back (often eased by leaning forward).
Serum amylase or lipase >=3 times the upper limit of normal (ULN) . Serum lipase is more sensitive and specific than amylase (stays elevated 8–14 days vs 3–5 days). Exam caveat: Serum amylase may be falsely normal in hypertriglyceridaemia (lipidaemic interference with optical assay) and chronic alcohol-related acute pancreatitis (acinar exhaustion).
Characteristic imaging features of acute pancreatitis on contrast-enhanced CT (CECT), MRI, or transabdominal ultrasound. (CECT is optimal at 72–96 hours post-symptom onset to assess pancreatic necrosis).
Severity Scoring — Modified Glasgow (Imrie) Prognostic Criteria:
Evaluated within the first 48 hours of admission.
Mnemonic PANCREAS :
- Letter Parameter Cut-off Threshold Pathophysiological Rationale
- P PaO2 <8.0 kPa (<60 mmHg) on room air Alveolar-capillary membrane damage; acute lung injury / ARDS
- A Age >55 years Diminished physiological reserve; higher mortality
- N Neutrophils (WBC) >15 x 10^9/L Severity of systemic inflammatory response syndrome (SIRS)
- C Calcium (corrected) <2.0 mmol/L Fat saponification; calcium binds free fatty acids in retroperitoneum
- R Renal (Urea) >16.0 mmol/L Severe third-space fluid depletion and prerenal azotaemia
- E Enzymes (LDH) >600 units/L (or AST >200 U/L) Widespread tissue necrosis and enzyme extravasation
- A Albumin (serum) <32 g/L Systemic capillary hyperpermeability and negative acute-phase state
- S Sugar (Glucose) >10.0 mmol/L Stress response and endocrine islet cell necrosis (in non-diabetics)
Clinical Scoring Interpretation: A score of >=3 points indicates severe acute pancreatitis , identifying patients at high risk of pancreatic necrosis, multi-organ failure, and death; mandates immediate High Dependency / Intensive Care Unit (HDU/ICU) admission.
Acute Management Principles:
Fluid Resuscitation: Goal-directed intravenous balanced crystalloids (Hartmann's solution) at 200–250 mL/h, titrated to urine output (>0.5 mL/kg/h) and normal haematocrit. Avoid fluid overload.
Analgesia: Intravenous opioids (fentanyl, morphine).
Nutritional Support: Early oral re-feeding (low-fat diet) as soon as pain subsides. If oral intake is not tolerated, enteral tube feeding (nasogastric or nasojejunal) is initiated within 48–72 hours. Enteral feeding maintains gut mucosal barrier integrity and reduces infectious complications compared to parenteral nutrition (TPN).
Antibiotics: Prophylactic antibiotics are strictly NOT recommended in sterile acute pancreatitis.
Urgent ERCP: Indicated within 24 hours for acute gallstone pancreatitis accompanied by concurrent acute cholangitis or persistent biliary obstruction.
Local Complications:
Pancreatic Pseudocyst: Encapsulated collection of amylase-rich fluid bounded by a non-epithelialized fibrous wall developing >4 weeks post-presentation. Asymptomatic pseudocysts are managed conservatively. Cysts >6 cm, symptomatic, or enlarging are drained endoscopically (cystogastrostomy) or radiologically; intervention should be delayed for at least 6 weeks to permit the fibrous wall to mature.
Walled-Off Pancreatic Necrosis (WON): Encapsulated collection of solid and liquid necrosis developing >4 weeks. If necrosis becomes infected (gas on CT or persistent sepsis), manage with the "step-up approach" : intravenous antibiotics (meropenem), percutaneous catheter drainage, and minimally invasive retroperitoneal or endoscopic necrosectomy.
Chronic Pancreatitis
Pathophysiology & Aetiology: Progressive, irreversible fibroinflammatory destruction of the pancreatic parenchyma, causing permanent loss of exocrine and endocrine tissue. Alcohol excess accounts for ~70% of UK cases; other causes include smoking, genetic mutations ( PRSS1 cationic trypsinogen gain-of-function, SPINK1 serine protease inhibitor loss-of-function, CFTR cystic fibrosis conductance regulator), hyperparathyroidism, ductal obstruction, and autoimmune pancreatitis (Type 1 IgG4-related).
Clinical Manifestations:
Recurrent or continuous epigastric abdominal pain radiating to the back, exacerbated 15–30 minutes after eating and eased by sitting forward.
Pancreatic Exocrine Insufficiency (PEI): Occurs when >90% of pancreatic enzyme secretory capacity is lost. Manifests as maldigestion, steatorrhoea (pale, bulky, foul-smelling, difficult-to-flush stools), weight loss, and fat-soluble vitamin malabsorption (vitamins A, D, E, K).
Pancreatic Endocrine Insufficiency: Destruction of islet cells produces secondary pancreatogenic Type 3c diabetes mellitus . Because both insulin-secreting beta cells and glucagon-secreting alpha cells are destroyed, patients experience extreme glycaemic volatility with high susceptibility to severe hypoglycemia.
Diagnostic Evaluation:
Fecal Elastase-1: The most sensitive and specific non-invasive laboratory test for pancreatic exocrine insufficiency. Human elastase-1 passes through the intestine without degradation. A value <200 ug/g stool is diagnostic of exocrine insufficiency (<100 ug/g indicates severe insufficiency) . Crucial clinical point: Exogenous porcine enzyme replacement does NOT cross-react with the human ELISA assay, permitting diagnostic testing while on therapy.
Abdominal CT / Plain Radiography: Demonstrates pathognomonic pancreatic parenchymal and intraductal calcifications , accompanied by pancreatic duct dilatation and parenchymal atrophy.
Medical Management:
Complete abstinence from alcohol and tobacco.
Pancreatic Enzyme Replacement Therapy (PERT, e.g. Creon): Enteric-coated porcine pancreatin capsules (lipase, amylase, protease) taken with all meals and snacks. Co-prescribing a proton pump inhibitor (PPI) elevates duodenal pH, preventing acidic inactivation of porcine lipase and optimizing therapeutic efficacy.
Fat-soluble vitamin supplementation (A, D, E, K) with regular bone mineral density surveillance.